Creo Medical has reported results for the six months to 31 December 2017 and provided commentary on a strong first year since listing in December 2016. Highlights of the year include regulatory clearance for its lead product, initiation of a ‘training led’ commercialisation plan and most significantly first patients treated with the Speedboat RS2 at two separate NHS sites. The company remains on track for a full commercial launch in 2019. We maintain our Buy recommendation.
20 Mar 2018
Strong first year on the market
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong first year on the market
Creo Medical Group Plc (CREO:LON) | 35.5 0.1 1.0% | Mkt Cap: 128.3m
- Published:
20 Mar 2018 -
Author:
Chris Donnellan -
Pages:
7
Creo Medical has reported results for the six months to 31 December 2017 and provided commentary on a strong first year since listing in December 2016. Highlights of the year include regulatory clearance for its lead product, initiation of a ‘training led’ commercialisation plan and most significantly first patients treated with the Speedboat RS2 at two separate NHS sites. The company remains on track for a full commercial launch in 2019. We maintain our Buy recommendation.